PMID- 17305500
OWN - NLM
STAT- MEDLINE
DCOM- 20070531
LR  - 20190911
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 8
IP  - 2
DP  - 2007 Feb
TI  - Targeting the RAS signaling pathway in malignant hematologic diseases.
PG  - 217-35
AB  - Molecularly targeting signaling pathways that are involved in the pathogenesis of 
      hematopoietic malignancies may lead to more specific and efficacious therapies. 
      Activation of the RAS signal transduction cascade is a common feature in the 
      molecular pathogenesis of hematologic malignancies. A number of novel agents 
      targeting RAS signaling have been developed over the past decade. This review 
      will focus on these agents, which include inhibitors of RAS post-translational 
      modification (farnesyl transferase (FTase)-, geranylgeranyl transferase-I 
      (GGTase-I)-, isoprenylcysteine carboxylmethyltransferase (ICMTase)-inhibitors, 
      statins, bisphosphonates), and inhibitors of RAF and MEK activity. Although some 
      of these inhibitors (e.g. FTase, RAF and MEK inhibitors) were developed to 
      specifically inhibit RAS signaling, it has become clear that RAS may not be the 
      only critical target of these compounds. This review provides a background on RAS 
      signaling in hematologic malignancies and discusses opportunities to exploit 
      aberrant cancer cell signaling in order to develop better treatment options for 
      patients suffering from these diseases.
FAU - Morgan, M A
AU  - Morgan MA
AD  - Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, 
      Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
FAU - Ganser, A
AU  - Ganser A
FAU - Reuter, C W M
AU  - Reuter CW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
RN  - 0 (Enzyme Inhibitors)
RN  - EC 3.6.1.- (GTP Phosphohydrolases)
SB  - IM
MH  - Enzyme Inhibitors/pharmacology
MH  - GTP Phosphohydrolases/*antagonists & inhibitors/metabolism
MH  - Hematologic Diseases/*metabolism
MH  - Humans
MH  - *Signal Transduction
RF  - 231
EDAT- 2007/02/20 09:00
MHDA- 2007/06/01 09:00
CRDT- 2007/02/20 09:00
PHST- 2007/02/20 09:00 [pubmed]
PHST- 2007/06/01 09:00 [medline]
PHST- 2007/02/20 09:00 [entrez]
AID - 10.2174/138945007779940043 [doi]
PST - ppublish
SO  - Curr Drug Targets. 2007 Feb;8(2):217-35. doi: 10.2174/138945007779940043.